Pharmacological properties of mifepristone: toxicology and safety in animal and human studies (Q44707949)

5 December 2017

Pharmacological properties of mifepristone: toxicology and safety in animal and human studies (English)

1 reference

5 December 2017

1 reference

1 reference

Regine Sitruk-Ware

1

1 reference

PubMed ID

14698070

5 December 2017

Irving M Spitz

series ordinal

2

1 reference

5 December 2017

1 December 2003

1 reference

5 December 2017

12

1 reference

inferred from page(s)

published in

Contraception

1 reference

5 December 2017

68

1 reference

5 December 2017

409-420

1 reference

5 December 2017

6

1 reference

Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Medical termination of pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

The steroid and thyroid hormone receptor superfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Progesterone receptors in reproduction: functional impact of the A and B isoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Effects of treatment of male and female rats in infancy with mifepristone on reproductive function in adulthood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Effects of long-term low-dose mifepristone on reproductive function in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

The New Steroid Analog RU 486 Inhibits Glucocorticoid Action in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

RU 486 inhibits peripheral effects of glucocorticoids in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Transient inhibition of RU 486 antiglucocorticoid action by dexamethasone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Peripheral antiglucocorticoid action of RU 486 in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Clinical Pharmacokinetics of Mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Pharmacokinetics of mifepristone after low oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Dose-response relationships of RU 486.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Mifepristone: contraceptive and non-contraceptive uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Study in 16,369 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Alterations in the pituitary-thyroid and pituitary-adrenal axes--consequences of long-term mifepristone treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Early pregnancy termination with mifepristone and misoprostol in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study--final results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

First trimester abortion with mifepristone and vaginal misoprostol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Mifepristone and misoprostol for early abortion when no gestational sac is present

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Treatment with mifepristone (RU486) and oestradiol facilitates the development of genital septic disease after copulation in female rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

A comparison of medical abortion (using mifepristone and gemeprost) with surgical vacuum aspiration: efficacy and early medical sequelae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Fetal malformation and failed medical termination of pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Development after exposure to mifepristone in early pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

The effects of RU-38486 on cervical ripening. Clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Induced cervical ripening with Mifepristone in first trimester abortion. A double-blind randomized biomechanical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Mifepristone (RU 486) for cervical priming prior to surgically induced abortion in the late first trimester.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

The use of mifepristone (RU 486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration. World Health Organization. Task Force on Post-ovulatory Methods for Fertility Regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Oral mifepristone 600 mg and vaginal gemeprost for mid-trimester induction of abortion. An open multicenter study. UK Multicenter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

Studies on the glucocorticoid-receptor blocking action of RU 38486 in cultured ACTH-secreting human pituitary tumour cells and normal rat pituitary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

7 January 2021

inferred from DOI database lookup

Pretreatment of the primigravid uterine cervix with mifepristone 30 h prior to termination of pregnancy: a double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

7 January 2021

inferred from DOI database lookup

Pre-operative cervical preparation before first trimester vacuum aspiration: a randomized controlled comparison between gemeprost and mifepristone (RU 486)

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900171-9

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/S0010-7824(03)00171-9

1 reference

5 December 2017

1 reference

PubMed ID

14698070